Brooklyn ImmunoTherapeutics names new Interim CEO, CFO (NASDAQ:BTX)
seekingalpha.com
finance
2022-05-31 11:53:39

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) on Monday has announced the appointment of Matt Angel as its interim chief executive officer and president. He will replace current CEO and President Howard J. Federoff, who departs to focus on building a new venture. Matt Angel is a biotechnology entrepreneur and executive, having led Factor Bioscience Inc. as CEO since its founding in 2011. He is co-founder of the immuno-oncology company, Exacis Biotherapeutics, where he serves as Scientific Advisory Board Chair, and the cell therapy company, Novellus Therapeutics, which was acquired by Brooklyn in 2021.
